Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

Trulieve Cannabis is back in focus after an updated fair value estimate edges from CA$19.53 to CA$20.36, a measured reset rather than a sweeping overhaul. That shift lines up with broader Street research, where analysts are fine tuning price targets while keeping long term theses largely intact. As you read on, you will see how this revised target fits into the evolving analyst narrative and what it could mean for how you track Trulieve from here.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Trulieve Cannabis.

• Several banks in the TransUnion coverage universe, including Morgan Stanley and Clear Street, have reiterated positive ratings even when fine tuning price targets. This shows how analysts can adjust valuation inputs while still seeing a solid long term case. You can use that pattern as a reference point when thinking about Trulieve’s refreshed fair value range.

• Clear Street has highlighted opportunities for companies to reset key narratives with investors around topics like AI and product positioning. For Trulieve, you can think about how management communication, capital allocation and execution against its stated plan might influence where your own fair value view lands within the updated CA$20.36 estimate.

• Across TransUnion coverage, firms such as Morgan Stanley, Goldman Sachs, Baird, Needham, Deutsche Bank, Stifel and Barclays have adjusted price targets. This reflects how quickly analyst models can shift when assumptions change. For Trulieve, any change in regulation, funding conditions or store level performance could similarly lead to valuation resets.

• The cluster of target revisions from multiple banks on the same day shows how sector wide pressures can influence analyst views at the same time. If cannabis sector headlines or policy updates turn less supportive, you should be prepared for Trulieve’s external valuations to be revisited, even without a dramatic change in its day to day operations.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

We’ve flagged 1 risk for Trulieve Cannabis. See which could impact your investment.

• A large medical review published in The Lancet reports limited evidence that cannabis based medicines are effective for many mental health and substance use disorders, with Trulieve Cannabis cited among several publicly traded sector peers.

• Dabstract is entering Maryland through a partnership with Trulieve Cannabis, bringing strain specific live resin High Terpene Extract oil products and vape formats to adult use and medical customers in the state.

• Trulieve Cannabis opened new medical cannabis dispensaries in DeLand and Lake Wales, Florida, offering in house and partner brands, home delivery, online ordering, and promotional discounts for veterans and first time customers.

• Trulieve Cannabis closed a private placement on 6 February 2026 with participation from 11 investors, following an earlier disclosure that it would receive US$13,500,000 in funding via convertible debt issued under Regulation D.